Amicus Therapeutics Inc. (NASDAQ:FOLD) was up 3.7% on Tuesday . The stock traded as high as $6.25 and last traded at $6.22, with a volume of 3,434,204 shares changing hands. The stock had previously closed at $6.00.

Several equities research analysts recently weighed in on FOLD shares. Goldman Sachs Group Inc. started coverage on Amicus Therapeutics in a report on Wednesday, March 30th. They set a “neutral” rating and a $10.00 target price for the company. Zacks Investment Research raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price target for the company in a research report on Monday. Leerink Swann reaffirmed an “outperform” rating and set a $19.00 price target (up previously from $17.00) on shares of Amicus Therapeutics in a research report on Tuesday, June 14th. Chardan Capital upped their price target on Amicus Therapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, April 12th. Finally, Robert W. Baird started coverage on Amicus Therapeutics in a research report on Wednesday, April 13th. They set a “neutral” rating and a $9.00 price target for the company. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Amicus Therapeutics has a consensus rating of “Buy” and an average target price of $12.19.

The stock’s market capitalization is $805.49 million. The stock has a 50-day moving average of $5.95 and a 200 day moving average of $6.85.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.01. On average, equities research analysts expect that Amicus Therapeutics Inc. will post ($1.35) earnings per share for the current fiscal year.

In other Amicus Therapeutics news, General Counsel Ellen Rosenberg purchased 15,000 shares of the stock in a transaction on Thursday, June 2nd. The shares were bought at an average cost of $7.67 per share, with a total value of $115,050.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

A number of large investors have bought and sold shares of FOLD. Jennison Associates LLC raised its stake in Amicus Therapeutics by 3.3% in the fourth quarter. Jennison Associates LLC now owns 4,123,955 shares of the biopharmaceutical company’s stock valued at $40,002,000 after buying an additional 133,138 shares during the last quarter. California Public Employees Retirement System raised its stake in Amicus Therapeutics by 3.7% in the fourth quarter. California Public Employees Retirement System now owns 326,100 shares of the biopharmaceutical company’s stock valued at $3,163,000 after buying an additional 11,600 shares during the last quarter. TD Asset Management Inc. raised its stake in Amicus Therapeutics by 1.5% in the fourth quarter. TD Asset Management Inc. now owns 178,700 shares of the biopharmaceutical company’s stock valued at $1,733,000 after buying an additional 2,600 shares during the last quarter. Swiss National Bank raised its stake in Amicus Therapeutics by 3.8% in the fourth quarter. Swiss National Bank now owns 140,200 shares of the biopharmaceutical company’s stock valued at $1,360,000 after buying an additional 5,100 shares during the last quarter. Finally, ProShare Advisors LLC raised its stake in Amicus Therapeutics by 15.6% in the fourth quarter. ProShare Advisors LLC now owns 117,318 shares of the biopharmaceutical company’s stock valued at $1,138,000 after buying an additional 15,789 shares during the last quarter.

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.